Income statement
USD
Annual
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -64M | -50M | -40M | -44M | -38M |
| EBITDA | -60M | -49M | -40M | -42M | -36M |
| Net Income | -63M | -52M | -38M | -41M | -36M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.91
-0.81% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Decibel Therapeutics, Inc. (DBTX) is a Healthcare stock with a market cap of $123.37M. The stock last traded around $4.91. Baseline metrics include revenue growth of 0.0%, EPS growth of -5.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -5.9%, free cash flow -30.7% with operating margin 0.0% and ROIC -61.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DBTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
DBTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
DBTX Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for DBTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$36.2M
+12.4% YoY
Free Cash Flow
-$37.4M
+25.5% YoY
Revenue Growth
+0.0%
EPS Growth
-5.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -64M | -50M | -40M | -44M | -38M |
| EBITDA | -60M | -49M | -40M | -42M | -36M |
| Net Income | -63M | -52M | -38M | -41M | -36M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35M | 36M | 28M | 19M | 11M |
| Total Assets | 123M | 184M | 67M | 43M | 93M |
| Total Liabilities | 42M | 43M | 230M | 27M | 36M |
| Shareholder Equity | 82M | 142M | -163M | 16M | 57M |
| Total Debt | 14M | 213K | 193K | 0 | 0 |
| Net Debt | -21M | -36M | -28M | -19M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
36M
+27.0% YoY
Capital Expenditures
1M
-79.4% YoY
Free Cash Flow
37M
+25.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-56.4%
Debt / Equity
0.17x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.